PLUS THERAPEUTICS, INC. 8-K

What Happened
Plus Therapeutics, Inc. (PSTV) announced in an 8-K filed April 9, 2026 that it has appointed Eric J. Daniels, M.D., as Chief Development Officer effective April 20, 2026. Dr. Daniels will lead development and regulatory efforts for the company’s pharmaceutical pipeline. His hire follows his recent role as Chief Development Officer at Kiora Pharmaceuticals (Oct 2021–Apr 2026) and other executive and founder roles at biotech companies.

Key Details

• Start date: April 20, 2026; 8-K filed April 9, 2026.
• Base salary: $460,000 per year. Target bonus: 40% of base salary.
• Equity awards: option to purchase up to 20,000 common shares (exercise price = fair market value on grant date; expected to vest monthly over 4 years with a one-year cliff) and 20,000 restricted stock units (RSUs) vesting quarterly over 3 years with a one-year cliff.
• Severance on involuntary termination without cause or resignation for good reason: 12 months’ base salary, target bonus for the year of termination, possibly the prior year’s bonus if unpaid, and 12 months of COBRA premium coverage; unvested equity will accelerate for the portion that would vest over the nine months following termination.
• No family relationships or related-party transaction disclosures were reported. The Daniels Employment Agreement is filed as Exhibit 10.1.

Why It Matters
This is a material executive hire focused on advancing Plus Therapeutics’ drug development and regulatory strategy. The compensation package includes cash pay, performance bonus, and equity incentives that align Dr. Daniels’ interests with long-term development goals. Investors should view this as management strengthening its development leadership; key follow-ups to watch are program updates, clinical milestones, and any changes in R&D timelines or expense guidance tied to development activities.